Company intelligence / Profile preview

Grannus BioSciences

San Diego, California, United States

Ownership: Private
Development stage: Other

Overview

Grannus BioSciences is a clinical-stage biotechnology company focused on the development of novel therapeutics for oncology. The company specializes in targeting the Heat Shock Protein 90 (Hsp90) pathway, a critical molecular chaperone involved in the folding and stability of numerous oncogenic proteins. Their lead candidate, GRN-300, is a small molecule Hsp90 inhibitor designed to provide improved efficacy and safety compared to previous generations of Hsp90-targeted drugs. Grannus is currently advancing GRN-300 through clinical trials for the treatment of advanced solid tumors, with a particular focus on genetically defined patient populations.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Grannus BioSciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Grannus BioSciences.

Explore the full profile